Immunotherapy dostarlimab gains FDA approval for treatment of recurrent and advanced endometrial cancer
https://www.facingourrisk.org/XRAY/dostarlimab-for-advanced-endometrial-cancer
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer
The FDA has given accelerated approval for the immunotherapy agent dostarlimab (Jemperli) to treat recurrent and advanced endometrial cancer that has a biomarker called mismatch repair deficiency (dMMR). This adds a new treatment option for people with recurrent or advanced endometrial cancer. (posted 5/18/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Is dostarlimab treatment an option for my endometrial cancer?
- What are the benefits and risks of treatment with dostarlimab?
- Is my tumor MMR deficient (dMMR) or MMR proficient (MMRp)?
- Given my tumor type, would you recommend dostarlimab for me?
- What other treatment options are there for my endometrial cancer?
- If I am treated with dostarlmab, what side effects might I experience? Given my health history, how risky are those side effects for me?
- Should I be tested for Lynch syndrome?
Open Clinical Trials
The following studies are enrolling people with advanced endometrial cancer.
- NCT04486352: A Study of Targeted Therapies for Patients With Recurrent Endometrial CancerA Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer. This study will test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab in people with recurrent endometrial cancer.
- NCT03607890: Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor. This study will evaluate the safety, effectiveness, and tolerability of the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability-high (MSI-H) solid tumors resistant to prior PD-(L)1 therapy.
- NCT03955978: Dostarlimab in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer. The purpose of this study is to evaluate dostarlimab compared to standard-of-care radiation therapy for patients with inoperable endometrial cancer to establish the safety and efficacy of inducing an anti-tumor immune response.
A number of other clinical trials for patients with endometrial cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.